Tech Company M&A Transactions
Javelin Pharmaceuticals Acquisition
Javelin Pharmaceuticals, operating out of Cambridge, was acquired by Myrexis. No transaction price was released.
Transaction Overview
Company Name
Acquired By
Announced On
12/21/2009
Transaction Type
M&A
Amount
Unknown
M&A Terms
The merger, which is expected to close in the first quarter of 2010, has been approved by the boards of both companies but must also be approved by the shareholders of each firm.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
125 CambridgePark Drive
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Email Address
Overview
Javelin is a specialty pharmaceutical company that applies innovative proprietary delivery technologies to develop new, improved formulations of existing drugs that target unmet and underserved medical needs in the growing pain management market.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Martin Driscoll
Chief Financial Officer
Stephen Tulipano
Chief Medical Officer
Daniel Carr
Vice President
Frederick Pierce
VP - R & D
Eric Lang
Browse more venture capital transactions:
Prev: 12/21/2009: Bluefly venture capital transaction
Next: 12/21/2009: EyeGate Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs